It is challenging to estimate the reinfection rate since most reinfected individuals are likely not tested, and/or oligo or asymptomatic. Yet, reinfection has been postulated to explain at least in part the 2nd wave of COVID-19 in Manaus (see bit.ly/3hyjVWk). 2/10
To address this, we tested serial samples from unvaccinated repeat blood donors from Manaus w a seroprevalence assay that wanes during convalescence. We assumed that reinfections induce a boosting ↗️ in antibody (Ab) levels, leading to V-shaped time series of Ab reactivity. 3/10
We selected 238 repeat donors based on their date of donation and partitioned them into 6 groups. These groups reflect the inferred sequence of infection and reinfection with non-P.1 and P.1 variants. 4/10
The Ab signal-to-cutoff (S/C) curves for the 6 groups (A–E) are shown below. Blue dots are positive donations (S/C>=0.49), red dots are negative donations, and donations of the same donors are connected by a line. 5/10
Cases of probable or possible reinfections (defined
by considering the time period when the antibody levels are expected to grow after recovery and
the range of half-lives for antibody waning after seroconversion) were also considered. 6/10
P.1 dominated in Manaus from Jan 2021 onwards (see bit.ly/3tRYfXz). Based on our classification criteria, we infer that of the presumed P.1 infections observed in 2021, between 16.9 (9.5%–28.5%) to 31.0% (21.4-42.5%) were reinfections. 7/10
There are several limitations of the study. For example, repeat negative donors may not represent truly unexposed individuals because sparse sampling may have resulted in missing the interval with a positive S/C signal. 8/10
Moreover, blood donors are biased towards asymptomatic and mild infections; therefore, our rates of reinfection cannot be extrapolated to persons with more severe primary infections. Despite these caveats 9/10
Our study suggests that reinfection due to P.1 is more frequent than what is typically detected by traditional epi, molecular and genomic surveillance of clinical cases. 10/10
CADDE preprint. A SARS-CoV-2 lineage of concern is growing rapidly in Manaus and across Brazil. Using a combination of genomic and epidemiological data, we characterise the emergence and altered characteristics of this new variant, P.1. Here is a short thread of our findings. 1/8
What makes P.1 different? The lineage has an unusually high number of mutations, including some previously implicated as important in other variants - including a trio in the spike protein (K417T, E484K & N501Y) associated with increased binding to the human ACE2 receptor. 2/8
Where did P.1 come from? Dating analyses show that this lineage emerged around early Nov 2020, in Manaus. In the weeks and months since it emerged, it has spread to multiple other states in Brazil; broadly following patterns in air travel. 3/8